ZOMDF (Zomedica) Beta: 1.1185 (As of Jun. 26, 2026)


What is Zomedica Beta?

Zomedica ZOMDF -5.00% Beta is 1.1185 as of Jun. 26, 2026. The stock has 3 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Zomedica's Beta is 1.1185.


Zomedica  (OTCPK:ZOMDF) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Zomedica Beta Related Terms


Zomedica Beta Historical Data

* Premium members only.

The historical data trend for Zomedica's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zomedica Beta Chart

Zomedica Annual Data
Trend Feb16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.91 0.72 1.51 2.47

Zomedica Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.02 1.92 2.34 2.47 1.64

ZOMDF vs RPID, STIM, OM: Beta Comparison

For the Medical Devices subindustry, Zomedica's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zomedica Beta vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Zomedica's Beta distribution charts can be found below:

* The bar in red indicates where Zomedica's Beta falls into.



Zomedica Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.1185 mean?
Zomedica (ZOMDF) has a Beta of 1.1185 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Zomedica and its competitors.
Is Zomedica's Beta too high?
Zomedica's current Beta is 1.1185.
How does Zomedica's Beta compare to RPID and STIM?
Zomedica's Beta of 1.1185 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Devices & Instruments company?
A good Beta depends on the Medical Devices & Instruments industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Zomedica and its competitors. Zomedica's current Beta is 1.1185. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zomedica stock overvalued right now?
Based on GuruFocus' analysis, Zomedica (ZOMDF) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.19, compared to a current price of $0.10 — trading 50% below its estimated fair value. The current Beta is 1.1185. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Zomedica (ZOMDF), the current Beta is 1.1185 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zomedica Business Description

Address 1101 Technology Drive, Suite 100, Ann Arbor, MI, USA, 48108
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its segments consist of Diagnostics, Therapeutic Devices, and Development Services. It earns the majority of revenue from the therapeutics segment, which consists of Assisi, PulseVet, and VETIGEL products.